Press release
Animal Drug Compounding Market to Witness a Pronounce Growth by 2024
View Report Details at: https://www.persistencemarketresearch.com/market-research/animal-drug-compounding-market.asp
According to Persistence Market Research’s report, titled “Animal Drug Compounding Market: Global Industry Analysis and Forecast, 2016-2024,” more than two-third of global sales of compounded animal drugs will remain concentrated in the US and Canada. North America’s animal drug compounding market is projected to witness revenue growth at 7% CAGR. On the other hand, other parts of the world will record sluggish growth in demand for animal drug compounding as value CAGRs in these regions are less likely to reach 5%.
View and Download TOC of Animal Drug Compounding Market Research Report@ https://www.persistencemarketresearch.com/market-research/animal-drug-compounding-market/toc
Global Animal Drug Compounding Market: Key Opportunities
The report cites that the popularity of alternate flavored dosage forms will favor the adoption of animal drug compounding. Veterinary drug compounders try to remove the bitter taste of the medicine and make it feel non-gritty, smooth, creamy thus contributing largely towards improved patient compliance. The better the ability of a compounding pharmacist in creating flavored dosages, the greater are the future revenue-generating opportunities for manufacturers. Companies such as Triangle Compounding Pharmacy Inc., Lorraine’s Pharmacy, Medisca Inc., WEDGEWOOD PHARMACY, Diamondback Drugs LLC, ESSENTIAL PHARMACY COMPOUNDING VET (Kohll’s Pharmacy & Homecare), and Slade Dispensary Services are profiled in the report as key manufacturers of compounded animal drugs in the world.
Request and Download Sample Report@ https://www.persistencemarketresearch.com/samples/12871
Availability of accreditation also enhanced sales prospects of compounded animal drugs. In the event of adverse events not being recorded, animal owners generally prefer to visit only accredited compounding pharmacies. In addition to this, lower availability of generic substitutes to veterinary drugs also propels the practice of compounding veterinary pharmaceuticals. Currently there is no reimbursement available for veterinary drugs, which indicate most of the drug expense goes out of pockets of animal owners. In such circumstances, most animal owners prefer resorting to compounded animal medications that are easily available, cheaper than branded equivalents and do not require multiple prescriptions.
Buy Full Animal Drug Compounding Market Report@ https://www.persistencemarketresearch.com/checkout/12871
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Animal Drug Compounding Market to Witness a Pronounce Growth by 2024 here
News-ID: 763311 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
